Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme.The clinical administration follows the Company's ...